CD47 expression may serve as a positive prognostic biomarker in metastatic NSCLC, correlating with better outcomes in patients treated with magrolimab plus docetaxel. Patients with metastatic ...

We are working closely with the FDA to bring this additional [darolutamide] treatment option to patients as soon as possible.

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Novocure has refined the transducer arrays that attach to Optune Gio, its wearable for glioblastoma treatment.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

The battle against breast cancer has produced significant triumphs in recent years, with new and tailored treatments now ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Knowing that every patient with metastatic prostate cancer who receives a first line of systemic treatment will eventually develop therapy resistance, e.g. against docetaxel or hormones, makes this ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

While stage 4 breast cancer is challenging, there are several effective treatment options available that can help manage the disease and improve quality of life.

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...